Drug Trial Radar · NCT06783647
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Jun 11, 2025
Primary completion
Dec 24, 2026
Study completion Dec 24, 2026
Sponsor
- Lead sponsor
- Nanjing Leads Biolabs Co.,LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Sun Yat-Sen University Cancer Center
- First posted
- Jan 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.
Conditions
- Advanced Solid Tumour
Interventions
LBL-024 for InjectionDrug
intravenous infusion.
Docetaxel InjectionDrug
intravenous infusion.
Bevacizumab InjectionDrug
intravenous infusion.
Pemetrexed Disodium for InjectionDrug
intravenous infusion.
Paclitaxel InjectionDrug
intravenous infusion.
Carboplatin InjectionDrug
intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Cancer Hospital
Hefei, Anhui, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Chest Hospital,Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
The First Affiliated Hospital of Guangdong Pharmaceutical University
Guangzhou, Guangdong, China · Recruiting
Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China · Recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Xiangyang Central Hospital
Xiangyang, Hubei, China · Recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Ganzhou People's Hospital
Ganzhou, Jiangxi, China · Recruiting
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China · Recruiting
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, China · Recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Recruiting
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China · Recruiting
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China · Recruiting
Mianyang Central Hospital
Mianyang, Sichuan, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.